# Appendix III

## Timeline of Our Reports

## 2013 - 2018

AGING ANALYTICS AGENCY
Invest for life

Biogerontology Research Foundation
Prevent. Restore. Preserve.

# Our Publications Timeline

DEEP KNOWLEDGE LIFE SCIENCES

LONGEVITY.INTERNATIONAL

## 2013

**2013 Regenerative Medicine Industry Framework**

(150 pages)

## 2014

**2014 Regenerative Medicine Analysis & Market Outlook**

(200 pages)


## 2015

**Big Data in Aging & Age-Related Diseases**

(200 pages)




**Stem Cell Market Analytical Report 2015**

(200 pages)




## 2016

**Longevity Industry Landscape Overview 2016**

(200 pages)


## 2017

**Volume I: The Science of Longevity**

(750 pages)


## 2018

**Volume II: The Business of Longevity**

(635 pages)


**Volume III: 10 Special Case Studies**


**Volume IV: Novel Financial Longevity Industry**


**Volume V: Regional Case Studies**

# Our Previous Reports

The Global Longevity Consortium, consisting of the Biogerontology Research Foundation, Deep Knowledge Life Sciences, Aging Analytics Agency and Longevity.International platform, have authored two major analytical reports on the Longevity Industry previously: Longevity Industry Landscape Overview *Volume I: The Science of Longevity, and Volume II: The Business of Longevity,* in addition to the previous reports produced by Aging Analytics Agency, which focused on broader biomedical sectors, such as their 2015 report *Big Data in Aging and Age-Related Diseases Industry Overview*, their 2014 report *Investing in Regenerative Medicine: Technology Analysis and Market Outlook*, and their 2013 report *Analytical Regenerative Medicine Industry Framework*.







# Our Previous Reports

*Volume I: The Science of Longevity,* set the landscape of geroscience against the backdrop of the 'silver tsunami' of global demographic aging, detailing the present state of precision, predictive and preventive medicine (referred to hereafter as 'P3'), how it works in conjunction with emerging preventative medical technologies, and the prospects for the next five years. It summarised the history and current state of development in geroscience, examined whether existing proposed solutions measure up to the impending problems. The consortium's first report tied together the progress threads of the constituent industries into a coherent narrative, mapping the intersection of biomedical gerontology, regenerative medicine, precision medicine, artificial intelligence, offering a brief history and snapshot of each. It also categorized, systematized and individually profiled 650 longevity-focused entities, including research hubs, non-profit organizations, leading scientists, conferences, databases, books and journals.

# Volume III:
# Special Case Studies

Biomarkers of Aging

Geroprotectors and Nutraceuticals

Gene Therapy

AI & Blockchain




P3 Medicine Clinics

Regenerative Medicine

Stem Cells

Novel Regulatory Approaches

**Framework for Optimal Industry Forecasting: Applying Technology Readiness Levels to Geroscience**

**Framework for Industry Optimization: Differentiating Valid Science from Overvalued, Hyped and Fraudulent Technologies**

# Novel Financial System
# 2022-2025 perspective

Longevity Venture Funds

BioPharma corporations in 2022-2025

Longevity Hedge Funds

Pension Funds

Insurance Companies

Longevity Derivatives


AgeTech Bank

Longevity Trust

Longevity Index Fund

Longevity Stock Exchange

Progressive Regulatory systems

Progressive Government Healthcare Systems

# Volume V:
# Regional Case Studies

USA

UK

European Union



Japan




Asia



Eastern Europe

Israel

Biogerontology Research Foundation
Prevent. Restore. Preserve.

# Longevity Industry in UK

## LANDSCAPE OVERVIEW

DEEP KNOWLEDGE VENTURES

SCIENCE, TECHNOLOGIES, COMPANIES, INVESTORS, TRENDS

# Our Previous Reports

In December 2017 Deep Knowledge Analytics released its inaugural report on the state of the AI for Drug Discovery industry, entitled AI for Drug Discovery Landscape Overview 2017, and in January 2018 released AI for Drug Discovery, Biomarker Development and Advanced R&D 2017. In April 2018, it also published an upgraded and much extended version of AI for Drug Discovery and Advanced R&D Q1.

These reports give in-depth coverage of the exponentially-growing global AI in Healthcare industry, with a specific focus on AI for drug discovery, biomarker development and advanced R&D, profiling the top companies, investors and influencers in the AI for drug discovery space.

On average, it takes about a decade of research — and an expenditure of $2.6 billion — to shepherd an experimental drug from lab to market. And because of concerns over safety and effectiveness, only about 5 percent of experimental drugs make it to market at all.

But drug makers and tech companies are investing billions of dollars in artificial intelligence with the hope that AI will make the drug discovery process faster and cheaper.


**AI FOR DRUG DISCOVERY, BIOMARKER DEVELOPMENT AND ADVANCED R&D LANDSCAPE OVERVIEW 2017**

www.dkv.global

DEEP KNOWLEDGE VENTURES



**AI for Drug Discovery Landscape Overview 2017**

www.dkv.global

DEEP KNOWLEDGE VENTURES


# AI in UK Healthcare

## Landscape Overview 2017

### TECHNOLOGY, COMPANIES, INVESTORS, TRENDS

- Digital Health Monitoring
- Drug Discovery
- Advanced R&D
- Medical Imaging and Diagnostics
- Hospital Management
- Patient Data
- Risk Analytics
- Surgery
- Lifestyle Management
- Virtual Assistants


# AI FOR DRUG DISCOVERY, BIOMARKER DEVELOPMENT AND ADVANCED R&D LANDSCAPE OVERVIEW 2018 / Q1

**Companies - 70**
**Investors - 180**
**Corporations - 20**
**R&D Centers - 20**

www.analytics.dkv.global

DEEP KNOWLEDGE VENTURES